Form 8-K

8-K — AIM ImmunoTech Inc.

Accession: 0001493152-26-028615

Filed: 2026-06-15

Period: 2026-06-12

CIK: 0000946644

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000946644

2026-06-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2026

AIM

IMMUNOTECH INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-27072

52-0845822

(State

or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS

Employer

Identification No.)

2117

SW Highway 484, Ocala, Florida

34473

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (352) 448-7797

Not

Applicable

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

symbol

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

AIM

NYSE

American

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01 Other Events.

June 15, 2026, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing that on June 12, 2026,

AIM received a letter from NYSE Regulation confirming that the Company has regained compliance with the continued listing standards

of the NYSE American LLC (“NYSE American”). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated

herein by reference.

The

letter stated that the Company is back in compliance with all of the NYSE American continued listing standards set forth in Part 10 of

the NYSE American Company Guide (the “Company Guide”). Specifically, the Company resolved the previously identified deficiencies

under Section 1003(a)(i), (ii), and (iii) of the Company Guide. As a result, the “below compliance” (“.BC”)

indicator will be removed from the Company’s trading symbol for its common stock and the Company will be taken off NYSE American’s

list of noncompliant issuers on its website. The Company will remain subject to NYSE American’s continued listing monitoring procedures

and remains committed to maintaining strong financial discipline and governance going forward.

Cautionary

Note Regarding Forward-Looking Statements

This

Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended

(the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

These statements are subject to risks and uncertainties that

could cause actual results to differ materially, including but not limited to risks related to NYSE

compliance, clinical development, regulatory approval,

and other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual

Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking

statements.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press

Release, dated June 15, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

June 15, 2026

AIM

ImmunoTech Inc.

/s/

Thomas K. Equels

Thomas

K. Equels

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

AIM ImmunoTech Regains NYSE American Compliance,

Company Resolves Stockholder Equity Deficiency

OCALA, Fla., June 15,

2026 / AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an

immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders, and

viral diseases, today announced that it has received written notice from the NYSE American that AIM has regained compliance with

NYSE American’s continued listing standards related to stockholders’ equity.

On May 7, 2026, the Company

entered into a warrant exercise inducement offer letter agreement with certain a holder of existing warrants, pursuant to which the

holders agreed to exercise their warrants in cash at a reduced exercise price for aggregate gross proceeds of approximately $3.5

million in consideration of the Company’s agreement to issue new warrants upon such exercise. On May 21, 2026, the Company

issued and sold 7,519,351 shares of common stock, par value $0.001 per share, and, in a concurrent private placement, Class I

warrants to purchase up to 15,038,702 shares of common stock to certain investors for aggregate gross proceeds of approximately $2.4

million. On June 10, 2026, the Company issued and sold 2,554,119 shares of common stock and, in a concurrent private placement,

771,503 shares of common stock, pre-funded warrants to purchase up to 1,782,616 shares of common stock, and Class J warrants to

purchase up to 10,216,476 shares of common stock to certain investors for aggregate gross proceeds of approximately $2.6 million.

Following the closing of these transactions, the Company believes it currently has stockholders’ equity in excess of the $6.0

million minimum requirement.

The NYSE American formally notified

the Company on June 12, 2026, confirming that the Company had successfully addressed and resolved all deficiencies related to Sections

1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. As a result, the “below compliance” (“.BC”)

indicator will be removed from the Company’s trading symbol for its common stock, and the Company will be removed from

NYSE American’s list of noncompliant issuers on its website. The Company will remain subject to NYSE American’s continued

listing monitoring procedures and remains committed to maintaining strong financial discipline and governance going forward.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused

on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic

cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown

broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com

and connect with the Company on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking

statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act

of 1934, as amended. amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this

press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: statements regarding

the Company’s ability to maintain compliance with NYSE American continued listing standards; the Company’s stockholders’

equity position and its ability to remain above the $6.0 million minimum requirement; Ampligen’s potential efficacy and applicability

in the treatment of Ebola virus disease and other conditions; the potential for prophylactic or early-onset therapeutic applications;

the timing of commencement, enrollment, completion, and results of clinical trials; intellectual property expansion and regulatory progress;

and the timing for receiving government approvals, if at all. For all forward-looking statements, the Company claims the protection

of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in

this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism

of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans,

and our objectives for future operations, are forward-looking statements. For this press release, words such as “believe,”

“may,” “might,” “will,” “could,” “should,” “can,” “estimate,”

“continue,” “anticipate,” “intend,” “expect,” “envision,” “potential”

and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement

is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances

that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether

Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures

in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future

activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required

to determine whether Ampligen® will be effective in the treatment of these conditions, including Ebola virus disease. Results obtained

in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not

Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful

or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack

of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated,

the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings

in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings

that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s

website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties

in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected

by these risks.

For a detailed discussion of these

and other risk factors, please review the “Risk Factors” section of the Company’s most recent Annual Report

on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC. These filings are available at

www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements, which speak only as of

the date of this press release. Except as required by applicable law, the Company does not intend to update, and expressly disclaims

any duty to update, any forward-looking statements to reflect events or circumstances after the date hereof or to reflect new

information, actual results, revised expectations, or the occurrence of unanticipated events. The information found on the

Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into

this press release.

Investor Contact:

JTC Team, LLC

Jenene Thomas

908.824.0775

AIM@jtcir.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (5968 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 19

v3.26.1

Cover

Jun. 12, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 12, 2026

Entity File Number

001-27072

Entity Registrant Name

AIM

IMMUNOTECH INC.

Entity Central Index Key

0000946644

Entity Tax Identification Number

52-0845822

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2117

SW Highway 484

Entity Address, City or Town

Ocala

Entity Address, State or Province

Entity Address, Postal Zip Code

34473

City Area Code

(352)

Local Phone Number

448-7797

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

AIM

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration